Bert Junno was elected new Chairman of the Board for the gene therapy company CombiGene during the Annual General Meeting in June. With extensive experience in the biotechnology industry and having founded five companies in the sector, Junno will be a valuable addition to the company's continued development. BioStock contacted Junno to find out more about his previous experiences and how he will make his mark on the company, which has a drug candidate for epilepsy and a project to develop a drug candidate for partial lipodystrophy in its pipeline.